The Ahmedabad-based company has launched 'Cadiflu-S', which is also the first Virus Like Particles (VLP) technology based influenza vaccine in the world.
The company claimed that it is the first entity in the country to develop a vaccine for seasonal influenza.
"Building on the success of 'Cadiflu-S', we will be launching a series of vaccines, including many first-of-its kind in the world, using novel technology platforms like VLPs and nanoparticles," Cadila Pharmaceuticals Chairman and MD Rajiv Modi said in a statement.
The plant has the capacity of producing up to 25 million doses of vaccine every year.
Also Read
Cadiflu-S does not contain any viruses, and is a major technological breakthrough since it completely eliminates the possibility of any infection to the vaccinated person from the vaccine, the company said.
Moreover, the VLP based vaccine does not contain any egg proteins, antibiotics or preservatives, and thus provides huge relief to people who are prone to allergies, it added.
CPL Biologicals has obtained all the necessary approvals from the concerned regulatory authorities for commercialisation of 'Cadiflu-S' vaccine.
Disclaimer: No Business Standard Journalist was involved in creation of this content